Christopher Bruno

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

15h-index785citations55works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotics Pharmacokinetics and Efficacy(22), Antibiotic Resistance in Bacteria(19), Pneumonia and Respiratory Infections(16), Nosocomial Infections in ICU(10), Antibiotic Use and Resistance(8)

Publications55 total

P-445. Susceptibility and molecular characterization of isolates from a Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in pediatric participants with gram-negative (GN) bacterial infection
Open Forum Infectious Diseases·2026Open Access
Evaluation of the effects of pregabalin for the management of hospitalized feral cats
Veterinary Anaesthesia and Analgesia·2025
Strategizing for Sustainability and Impact in Complex Environments
Academy of Management Proceedings·2025
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
International Journal of Infectious Diseases·2024· 3 citedOpen Access
Navigating Political Polarization: Organizational Challenges and Strategic Responses
Academy of Management Proceedings·2024
Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial
The Lancet Infectious Diseases·2024· 41 cited
A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia
Antimicrobial Agents and Chemotherapy·2024· 4 citedOpen Access
Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence
Future Microbiology·2024· 9 citedOpen Access
P21 A Phase 3 randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability and immunogenicity of a 21-valent PCV, V116, in pneumococcal vaccine-naive adults (STRIDE-3)
JAC-Antimicrobial Resistance·2024Open Access
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
Microbiology Spectrum·2023· 3 citedOpen Access
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection
The Pediatric Infectious Disease Journal·2023· 18 citedOpen Access
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
Annals of Intensive Care·2023· 11 citedOpen Access
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
The Pediatric Infectious Disease Journal·2023· 25 citedOpen Access
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem
Critical Care·2022· 11 citedOpen Access
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia
The Journal of Clinical Pharmacology·2022· 6 citedOpen Access
Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
Annals of Clinical Microbiology and Antimicrobials·2022· 8 citedOpen Access
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis
The Journal of Clinical Pharmacology·2022· 2 citedOpen Access
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections
International Journal of Infectious Diseases·2022· 17 citedOpen Access
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial
Journal of Antimicrobial Chemotherapy·2022· 21 cited
Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
Antimicrobial Agents and Chemotherapy·2022· 6 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jennifer A. Huntington(20), Elizabeth G. Rhee(19), Brian Yu(14), Matthew G. Johnson(11), Erin Jensen(10), Marin H. Kollef(8), Carisa De Anda(8), Zufei Zhang(8), Ignacio Martín‐Loeches(7), Richard G. Wunderink(7), Hwa-ping Feng(7), Mekki Bensaci(6), Julia Lonchar(5), Feng-Hsiu Su(5), Jill Fiedler‐Kelly(5), Wei Gao(5), Mary Motyl(5), Álvaro Réa-Neto(4), Joan R. Butterton(4), Eric Mangin(4)